Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Monoclonal antibody 170

Next Previous
X
Search
Drug Profile

Monoclonal antibody 170

Alternative Names: Tru-Scint AD

Latest Information Update: 13 May 2003

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biomira
  • Class Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 13 May 2003 Monoclonal antibody 170 is available for licensing (http://www.biomira.com)
  • 04 Sep 2001 Discontinued - Phase-II/III for Breast cancer (diagnosis, recurrent) in USA (Injection)
  • 04 Sep 2001 Discontinued-II for Ovarian cancer (diagnosis) in Germany (Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top